Our strategic planning of therapeutic areas for development of new and generic drugs, as well as cellular products is based on the in-depth analysis of the patient population needs in the Russian Federation for various medical products and treatments. Currently, we are pursuing research and development of therapies for the following diseases and pathological conditions.
Ischaemic damage of the central nervous system (cerebrovascular stroke).
Strokes are one of major causes of death and disability in Russia and in the World.
Currently there is no common and easy-to-use treatment that can reduce the amount of damage to the nervous system in case of an acute cerebrovascular insufficiency. Thrombolytic medications can have a positive impact on the outcome of the disease if they are applied in the first few hours after the onset of symptoms in a hospital. However, delivery of the patient to the hospital, necessary testing and treatment administration within 3 hours of the onset of the stroke symptoms are rarely possible. In this situation, the medications promoting survival of nervous tissue after ischaemia are of a prime importance. In collaboration with the State Foundation Institute of Pharmacology of the Russian Academy of Medical Sciences (SF IPh RAMS) and the University of South Florida, “IBC “Generium” is developing novel therapeutics to fulfil this need.